Volume 83, Issue 1 pp. 30-38
ORIGINAL ARTICLE

Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations

Xiaohao Ruan MD

Xiaohao Ruan MD

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for more papers by this author
Da Huang MD

Da Huang MD

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for more papers by this author
Jingyi Huang MD

Jingyi Huang MD

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for more papers by this author
Danfeng Xu MD, PhD

Corresponding Author

Danfeng Xu MD, PhD

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence Danfeng Xu, MD, PhD, Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China.

Email: [email protected]

Rong Na, MD, PhD, Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, China.

Email: [email protected]

Search for more papers by this author
Rong Na MD, PhD

Corresponding Author

Rong Na MD, PhD

Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China

Correspondence Danfeng Xu, MD, PhD, Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China.

Email: [email protected]

Rong Na, MD, PhD, Division of Urology, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, China.

Email: [email protected]

Search for more papers by this author
First published: 22 August 2022
Citations: 2

Xiaohao Ruan and Da Huang contributed equally to this work.

Abstract

Background

Polygenic risk score (PRS) has shown promise in predicting prostate cancer (PCa) risk. However, the application of PRS in non-European ancestry was poorly studied.

Methods

We constructed PRS using 68, 86, or 128 PCa-associated single-nucleotide polymorphisms (SNPs) identified through a large-scale Genome-wide association study (GWAS) in the European ancestry population. A calibration approach was performed to adjust the PRS exact value for each ancestry. The study was conducted in East Asian (ChinaPCa Consortium, n = 2379), European (UK Biobank, n = 209,172), and African American (African Ancestry Prostate Cancer Consortium, n = 6016).

Results

Individuals with the highest PRS (in >97.5th percentile) had over 2.5-fold increased risk of PCa than those with average PRS (in 40th–60th percentile) in both European (odds ratio [OR] = 3.79, 95% confidence interval [CI] = 3.46–4.16, p < 0.001) and Chinese (OR = 2.87, 95% CI = 1.29–6.40, p = 0.010), while slightly lower in African American (OR = 1.77, 95% CI = 1.22–2.58, p = 0.008). Compared with the lowest PRS (in <2.5th percentile), increased PRS was also associated with the earlier onset of PCa (All log-rank p < 0.05). The highest PRS contributed to having about 5- to 12-fold higher lifetime risk and 5–10 years earlier at disease onset than the lowest category across different ancestry populations.

Conclusion

We demonstrated that European-GWAS-based PRS could also significantly predict PCa risk in Asian ancestry and African ancestry populations.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

Data used in this research are publicly available to qualified researchers on application to the UK Biobank (www.ukbiobank.ac.uk) and the dbGaP (www.ncbi.nlm.nih.gov/projects/gap/; ID: phs001391. v1. p1).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.